Feng Yumei, Zhou Ping, Duan Xirui, Ye Qin, Xie Ke
Department of Oncology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China.
Am J Clin Oncol. 2025 Oct 1;48(10):488-495. doi: 10.1097/COC.0000000000001204. Epub 2025 May 5.
The incidence of head and neck cancer ranks sixth among malignant tumors in the world. According to the GLOBOCAN 2020 database, there are about 930,000 new cases and 467,000 deaths per year. Among malignant head and neck tumors, head and neck squamous cell carcinoma (HNSCC) comprises approximately 90% of cases. Between 70% and 80% of HNSCC patients are diagnosed at an advanced stage (III or IV). Following comprehensive treatment, the recurrence rate within 2 years ranges from 40% to 60%. In cases of recurrent or metastatic HNSCC, the median survival period after traditional chemotherapy or targeted therapy is about 1 year, with a 5-year survival rate below 10%. However, several current trials are examining new tactics, such as better prediction biomarkers and combination strategies with chemotherapy, targeted therapy, additional immunotherapy, or radiotherapy, given the relatively poor response rate of immune checkpoint inhibitor monotherapy. Consequently, the research on stereotactic body radiation therapy (SBRT) in conjunction with immunotherapy for locally advanced head and neck tumors is reviewed in this article.
头颈癌的发病率在全球恶性肿瘤中位列第六。根据2020年全球癌症负担（GLOBOCAN）数据库，每年约有93万新发病例和46.7万例死亡病例。在恶性头颈肿瘤中，头颈鳞状细胞癌（HNSCC）约占病例的90%。70%至80%的HNSCC患者在晚期（III期或IV期）被诊断出来。经过综合治疗后，2年内的复发率在40%至60%之间。对于复发或转移性HNSCC病例，传统化疗或靶向治疗后的中位生存期约为1年，5年生存率低于10%。然而，鉴于免疫检查点抑制剂单药治疗的缓解率相对较低，目前有几项试验正在研究新策略，如更好的预测生物标志物以及与化疗、靶向治疗、额外免疫治疗或放疗的联合策略。因此，本文综述了立体定向体部放疗（SBRT）联合免疫治疗局部晚期头颈肿瘤的研究。
